From the ten-year epidemiological study evaluated by FDA, it was not particularly revealed about the possibility that Actos (pioglitazone) might be consociated with bladder cancer. But, on June, 2011, within a span of nine months from the revelation of the previous report, FDA Actos recall stated that patients using Actos for a prolonged period or at high dose might be found consociated with an extended risk of bladder cancer. The Agency expressed that wanted to be utterly sure before releasing such warning. Now, it would be too early to say that if FDA Actos recall has suffered from unnecessarily delay. Although, the Agency has assured that they will be coming out with a detailed report about Actos cancer dangers, but they are not expected t bring out such report anytime before 2012. In spite of being not supported with the official release of such warning, Actos affected patients can file lawsuits for medical compensation under the good advise of Actos lawyers.

(Sponsored Attorney Advertising)